HLB Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2019	FY 2018	FY 2017
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
Cash & Equivalents	4,342	7,609	10,492	2,744	3,030	5,350
Short-Term Investments	15,529	14,528	11,500	1,310	235	525
Trading Asset Securities	-	-	-	11,109	5,842	5,514
Cash & Short-Term Investments	19,871	22,137	21,992	15,163	9,107	11,389
Cash Growth	-9.65%	0.66%	45.04%	66.50%	-20.04%	-
Accounts Receivable	24,786	22,833	16,095	7,910	6,044	6,382
Other Receivables	1,077	1,395	1,408	156.15	163.97	128.86
Receivables	25,862	24,227	17,504	8,066	6,218	6,521
Inventory	29,437	29,526	22,861	5,648	5,382	4,884
Prepaid Expenses	179.32	151.11	178.25	47.26	428.26	242.13
Other Current Assets	1,886	660.69	845.65	93.85	140.41	230.82
Total Current Assets	77,235	76,702	63,381	29,018	21,275	23,267
Property, Plant & Equipment	46,010	44,388	34,020	15,315	13,304	13,323
Long-Term Investments	75,388	45,204	55,078	146.5	1,265	1,789
Goodwill	105.07	105.07	-	-	-	-
Other Intangible Assets	3,379	3,670	4,448	446.2	282.13	188.45
Long-Term Deferred Tax Assets	-	-	-	208.27	6.99	1,002
Long-Term Deferred Charges	134.97	185.53	387.79	629.76	129.67	-
Other Long-Term Assets	398.28	428.28	620.27	82.12	160.27	277.32
Total Assets	202,650	170,682	157,933	45,846	36,423	39,846
Accounts Payable	10,346	10,257	8,718	2,404	4,856	2,261
Accrued Expenses	8,371	6,619	8,133	4,593	2,092	2,241
Short-Term Debt	15,000	15,000	15,000	8,458	4,854	1,725
Current Portion of Long-Term Debt	-	-	-	780	1,580	10,388
Current Portion of Leases	1,498	1,540	763.8	426.67	-	-
Current Income Taxes Payable	-	-	-	-	105.9	-
Other Current Liabilities	5,522	6,212	6,017	6,429	2,736	1,126
Total Current Liabilities	40,738	39,628	38,632	23,092	16,224	17,741
Long-Term Debt	-	-	-	1,580	1,260	2,840
Long-Term Leases	3,824	4,144	290.77	1,954	-	-
Pension & Post-Retirement Benefits	1,701	1,436	937.15	1,166	1,521	2,375
Long-Term Deferred Tax Liabilities	4,657	325.35	1,672	-	314.93	-
Other Long-Term Liabilities	-	0	0	151.41	105.72	88.99
Total Liabilities	50,920	45,534	41,532	27,943	19,425	23,045
Common Stock	16,400	16,400	15,907	6,924	6,924	6,247
Additional Paid-In Capital	61,981	61,981	93,433	8,435	17,304	15,263
Retained Earnings	57,088	56,368	1,971	1,215	-8,453	-5,410
Treasury Stock	-5.6	-5.6	-5.6	-5.6	-5.6	-5.6
Comprehensive Income & Other	16,268	-9,594	5,096	1,334	1,229	707.13
Shareholders' Equity	151,731	125,149	116,402	17,903	16,998	16,802
Total Liabilities & Equity	202,650	170,682	157,933	45,846	36,423	39,846
Total Debt	20,321	20,684	16,055	13,198	7,694	14,953
Net Cash (Debt)	-450.64	1,453	5,938	1,965	1,413	-3,564
Net Cash Growth	-	-75.53%	202.18%	39.05%	-	-
Net Cash Per Share	-13.71	44.45	185.20	141.88	104.39	-297.72
Filing Date Shares Outstanding	32.73	32.8	31.81	13.85	13.85	12.49
Total Common Shares Outstanding	32.73	32.8	31.81	13.85	13.85	12.49
Working Capital	36,498	37,073	24,749	5,927	5,052	5,526
Book Value Per Share	4635.60	3815.65	3658.77	1292.83	1227.52	1344.92
Tangible Book Value	148,247	121,374	111,954	17,457	16,716	16,613
Tangible Book Value Per Share	4529.16	3700.57	3518.98	1260.61	1207.15	1329.84
Land	26,792	26,792	26,792	1,239	1,239	1,239
Buildings	2,172	3,697	3,697	8,520	8,472	8,581
Machinery	15,863	15,616	15,770	9,673	8,772	9,892
Construction In Progress	8,488	6,523	1,658	382.9	183.6	136.94